Saip, P. Et Al. 2013. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial. BREAST , vol.22, no.5 , 628-633.

Saip, P., Eralp, Y., Sen, F., Karaca, H., ÖZKAN, M., Cetin, B., ... Benekli, M.(2013). Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial. BREAST , vol.22, no.5, 628-633.

Saip, P. Et Al. "Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial," BREAST , vol.22, no.5, 628-633, 2013

Saip, P. Et Al. "Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial." BREAST , vol.22, no.5, pp.628-633, 2013

Saip, P. Et Al. (2013) . "Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial." BREAST , vol.22, no.5, pp.628-633.

@article{article, author={P. Saip Et Al. }, title={Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial}, journal={BREAST}, year=2013, pages={628-633} }